Angiodynamics (ANGO) Common Equity (2011 - 2026)

Angiodynamics' Common Equity history runs 16 years deep, the most recent figure standing at $170.8 million for Q2 2026.

• Quarterly Common Equity fell 6.64% year-over-year to $170.8 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $170.8 million (down 6.64% YoY) and the FY2026 annual result came in at $170.8 million, down 6.64% from the prior year.
• Common Equity was $170.8 million for Q2 2026 at Angiodynamics, down from $173.4 million in the prior quarter.
• Across five years, Common Equity topped out at $429.7 million in Q1 2022 and bottomed at $170.8 million in Q2 2026.
• A 5-year average of $286.5 million and a median of $212.1 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity advanced 3.32% — and 2024, when it sank 54.05%.
• Angiodynamics' Common Equity stood at $408.0 million in 2022, then fell by 1.65% to $401.2 million in 2023, then sank by 53.45% to $186.8 million in 2024, then decreased by 5.59% to $176.3 million in 2025, then decreased by 3.12% to $170.8 million in 2026.
• Business Quant data shows ANGO's Common Equity at $170.8 million in Q2 2026, $173.4 million in Q1 2026, and $176.3 million in Q4 2025.